The Breakthrough DDS Technology

Pray attend to the novel contrivance: The Breakthrough DDS Technology. The SemiBioFinTex's DDS platform doth combine a multitude of technologies to enhance the oral absorption and bioavailability of endogenous peptides in a stable manner, standing as the very first such innovation known to science and commerce.

Historically, the requirement of high dosages hath rendered oral analogue peptides difficult to scale, which did favour the development of small-molecule alternatives for the reduction of corpulence. Furthermore, even the earliest data from the newest platforms (those presently designated with an INN), concerning small-molecule analogues, doth suggest a reduced efficacy and more frequent side effects when set against peptides. Neither other platforms, designed to surmount these challenges, have enabled the effective oral administration of analogue peptides at doses potentially far lower than other oral peptides currently in development.

The SemiBioFinTex's DDS platform is designed for the oral administration and injection of APIs both great and small (including, but not restricted to, mAbs, vaccines, proteins, mRNA, endogenous peptides [GLP-1, GIT, insulin]). It maketh no use of any manner of artificial enhancer, neither for transport, absorption, nor for the stability of the transported API, and doth not moderate endogenous APIs. This doth constitute the platform as the first not-too-much ado about breakthrough in the methods of transport for large and small molecules, nanobiotechnology, DNA/RNA techniques, polyclonal products development, and many other strategic areas of healthcare.

The revolutionary aspect is the sole, worldwide plausibility of this DDS to deliver orally ENDOGENOUS peptides and unmodified large molecules, achieving a bioavailability (BA) in animal studies that doth cross the barrier of fifty to ninety per cent. This feat, excluding cyclosporine (and its derivatives or similar cyclic compounds), is the BiC (best in class) and the FiC (first in class) achievement. Add to this a completely biocompatible DDS chemical structure (GRAS), and one is verily in the presence of a miracle, by the Holy Spirit.

With high probability with SemiBioFinTex:

• no longer any peptide analogs are needed - since the DDS delivers natural GLP-1, GIT, insulin, with almost 99% BA.
• No longer highly inefficient LNP m-RNA vaccines are needed (due to 99% efficient endosomal escape of the DDS).
• No longer threats about antitumour therapies are needed (amid applications of DDS to PDA and PDD).